Skip to Content
GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vidler Water Resources, Inc. (Nasdaq - VWTR), Antares Pharma, Inc. (Nasdaq - ATRS), Sierra Oncology Inc. (Nasdaq - SRRA), SailPoint Technologies Holdings, Inc. (NYSE - SAIL)

BALA CYNWYD, Pa., April 14, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Vidler Water Resources, Inc. (Nasdaq - VWTR)       

Under the terms of the agreement, Vidler will be acquired by D.R. Horton, Inc. (“D.R. Horton”) (NYSE - DHI). Vidler stockholders will receive $15.75 in cash per share. The investigation concerns whether the Vidler Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether D.R. Horton is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/vidler-water-resources-inc-nasdaq-vwtr/.

Antares Pharma, Inc. (Nasdaq - ATRS)

Under the terms of the agreement, Antares will be acquired by Halozyme Therapeutics, Inc. (“Halozyme”) (Nasdaq - HALO). Antares stockholders will receive $5.60 in cash per share, in a deal valued at $960 million. The investigation concerns whether the Antares Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Halozyme is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/antares-pharma-inc-nasdaq-atrs/.

Sierra Oncology Inc. (Nasdaq - SRRA)

Under the terms of the agreement, Sierra will be acquired by GlaxoSmithKline Plc (“GSK”) (NYSE - GSK). Under the terms of the agreement, Sierra stockholders will receive $55.00 in cash per share. The investigation concerns whether the Sierra Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether GSK is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/sierra-oncology-inc-nasdaq-srra/.  

SailPoint Technologies Holdings, Inc. (NYSE - SAIL)   

Under the terms of the agreement, SailPoint will be acquired by be acquired by Thoma Bravo. SailPoint stockholders will receive $65.25 in cash per share, representing a total transaction value of $6.9 billion. The investigation concerns whether the SailPoint Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Thoma Bravo is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/sailpoint-technologies-holdings-inc-nyse-sail/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo